LCM
ADPT icon

Legato Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Legato Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Buy
273,441
+121,102
+79% +$1.86M 0.49% 33
2026
Q1 		$2.11M Sell
152,339
-86,269
-36% -$1.37M 0.19% 163
2025
Q4 		$3.87M Buy
238,608
+595
+0.2% +$9.71K 0.33% 52
2025
Q3 		$3.56M Buy
238,013
+55,985
+31% +$682K 0.39% 55
2025
Q2 		$2.12M Sell
182,028
-426
-0.2% -$3.87K 0.25% 106
2025
Q1 		$1.36M Sell
182,454
-2,214
-1% -$17K 0.18% 179
2024
Q4 		$1.11M Sell
184,668
-56,690
-23% -$313K 0.14% 265
2024
Q3 		$1.24M Buy
241,358
+31,656
+15% +$138K 0.15% 238
2024
Q2 		$759K Buy
209,702
+81,648
+64% +$259K 0.1% 330
2024
Q1 		$411K Hold
128,054
– – 0.05% 471
2023
Q4 		$627K Buy
128,054
+30,560
+31% +$139K 0.08% 364
2023
Q3 		$531K Sell
97,494
-2,543
-3% -$16.8K 0.08% 387
2023
Q2 		$671K Buy
100,037
+28,354
+40% +$211K 0.09% 352
2023
Q1 		$633K Buy
+71,683
New +$632K 0.12% 305

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Legato Capital Management's ADPT Position: Q2 2026 in Review

Legato Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 79% in Q2 2026, buying an estimated $1.86M and bringing the position to 273,441 shares worth $5.87M. The position accounts for 0.49% of the portfolio, ranked #33.

Legato Capital Management first reported a position in ADPT in Q1 2023 and has held it in 14 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Legato Capital Management held 273,441 shares of Adaptive Biotechnologies worth $5.87M as of Q2 2026.
  • Legato Capital Management bought 121,102 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.86M.
  • Adaptive Biotechnologies made up 0.49% of Legato Capital Management's portfolio in Q2 2026, its #33 holding.
  • Legato Capital Management first reported a position in Adaptive Biotechnologies in Q1 2023 and has held it in 14 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.